drugset

drugset / Trial / NCT00429377

Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study

NCT00429377 ↗

Phase 3 Completed 64 enrolled Astellas Pharma Inc

RandomizedParallel-groupDouble-blindTreatment

Summary

This study consists of a 28-week placebo-controlled double-blind inter-group efficacy study in steroid refractory Lupus Nephritis patients.

Timeline

Start: 2003-06
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tacrolimus	Small molecule	—	—

Indications